期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 64, 期 22, 页码 16609-16625出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.1c01204
关键词
-
资金
- Research Grants Council of Hong Kong [22301719]
- Biotechnology and Biological Research Council
- Wellcome Trust [106244/Z/14/Z]
- Cancer Research UK
- Felix Scholarship
- Diamond Light Source
- Wellcome Trust [106244/Z/14/Z] Funding Source: Wellcome Trust
FTO catalyzes the modification of nucleic acids, including demethylation of m(6)A in mRNA, and is a proposed target for anti-cancer therapy. By using crystal structures, potent and selective FTO inhibitors were designed and synthesized, showing selectivity over other clinically targeted 2OG oxygenases. The results suggest that structure-based design can enable the development of effective FTO inhibitors for in vivo use.
FTO catalyzes the Fe(II) and 2-oxoglutarate (2OG)-dependent modification of nucleic acids, including the demethylation of N-6-methyladenosine (m(6)A) in mRNA. FTO is a proposed target for anti-cancer therapy. Using information from crystal structures of FTO in complex with 2OG and substrate mimics, we designed and synthesized two series of FTO inhibitors, which were characterized by turnover and binding assays, and by X-ray crystallography with FTO and the related bacterial enzyme AlkB. A potent inhibitor employing binding interactions spanning the FTO 2OG and substrate binding sites was identified. Selectivity over other clinically targeted 2OG oxygenases was demonstrated, including with respect to the hypoxia-inducible factor prolyl and asparaginyl hydroxylases (PHD2 and FIH) and selected JmjC histone demethylases (KDMs). The results illustrate how structure-based design can enable the identification of potent and selective 2OG oxygenase inhibitors and will be useful for the development of FTO inhibitors for use in vivo.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据